Startup Rise America News’ Post

#Topics Awz Ventures Leads $6M Funding in NanoPass Technologies [ad_1] NanoPass Technologies, a company specializing in intradermal delivery solutions, secured a $6 million funding round, from which, lead investor Awz Ventures invested $4 million. The investment aims to support NanoPass’s commercial expansion and innovation efforts. Daniel Levitats, with over 25 years of experience in high-tech and medical device companies, has been appointed as the new CEO to lead the company’s growth initiatives. The company’s flagship product is the MicronJet™ platform, which utilizes Micro Electro Mechanical Systems (MEMS) technology for intradermal delivery. The platform features a proprietary pure silicon crystal-made hollow pyramid structure, which is FDA-cleared for intradermal delivery and is smaller than 1 mm in size. MicronJet™ has been clinically proven to provide high delivery consistency, low leakage rates, and high success rates in over 70 clinical studies. The MicronJet™ platform is designed to optimize product delivery performance in both therapeutic and aesthetic procedures. It offers precision, consistency, and safety that surpasses traditional injection methods. The near-painless nature of the delivery system has made it a preferred choice for clinicia...

Biotech startups are jumping aboard the mega round-bound train. Investors are happy to greet them, as long as the drug developers have treatments in the clinic or can soon gather human trial data with the capital. A look at the 21 nine-figure financings so far in the first quarter: #biotech #megaround #venturecapital #lifesciences #funding #drugdevelopment #biotechstartups #fundraising #investment #familyoffices

Arie Belldegrun has yet another job: He wants to be your lender. Belledegrun and his team just announced they have raised more than $600 million for a new life science credit firm called Symbiotic Capital. Symbiotic said it will provide loans to biotechs, companies manufacturing medical devices and health care tools, sequencing firms, and synthetic biology companies, and more. I spoke to Belldegrun about why he wanted to start this credit company and why he hired industry experts like Roche CEO Franz Humer and Polaris Partners' Amy Schulman. #lifesciences #startups #biotech #pharma #financing #loans #credit #medicaldevice #healthtech #startupstrategies #financialstrategies

Enveda Biosciences Secures $55M to Advance AI-Driven Drug Discovery - Major Funding Round: Enveda Biosciences, a biotech firm specializing in AI-driven drug discovery, raised $55M in a Series B2 round, bringing total funding to $230M. - Strategic Investors: New investors include Premji Invest, Lingotto Investment Fund, Microsoft, and The Nature Conservancy, with continued support from existing backers. - Advancing Drug Development: Funds will enhance Enveda’s AI platform and support Phase I clinical trials for three lead programs, including a novel treatment for atopic dermatitis. Subscribe to our daily newsletter here for more AI news https://lnkd.in/d_cKz6EH #AI #Healthcare #Innovation #Technology #Future #Startups #Entrepreneurship #VentureCapital #ArtificialIntelligence #DigitalMarketing

Following the FDA’s recent decision to tighten regulations for clinical laboratories, RTW Investments, LP Partner and Portfolio Manager Naveen Yalamanchi recently spoke with the The Wall Street Journal Journal’s Brian Gormley to discuss the impact this will have on lab-testing startups and the venture capital firms that invest in them. Read the full article here (subscription required): https://lnkd.in/epi7vtGm #Biotech #LDTs #Investing #Regulation

Biopharma, Finance Vets Launch $600 Million Life Science Loan Firm There's a new source of funding for life science companies in town, providing credit as an alternative to other financing avenues such as venture capital. Symbiotic Capital – which starts life with more than $600 million at its disposal, is an affiliate of Bellco Capital, an investment form set up by Arie Belldegrun, a biotech entrepreneur formerly chief executive of Kite Pharma and currently executive chairman of Allogene. The company describes itself as a first-of-its-kind provider of "credit partnerships" that will provide financing to "compelling life science companies to support scientific innovation across biotechnology, medical devices, diagnostics, tools, synthetic biology, and other healthcare subsectors." It will mainly target companies with projects in later-stage development or already on the market. https://lnkd.in/g68BG2_G #aspenalert #biotech #bioprocess

- Over the past 12 weeks, biotech startups have seen a resurgence in $100 million-plus financings, reminiscent of the market peak three years ago. - This week alone, three startups secured significant funding: Engrail Therapeutics ($157 million), Clasp Therapeutics ($150 million), and Capstan Therapeutics ($175 million). - This year has witnessed 21 companies securing nine-figure megarounds, driven partly by investors now favouring projects with clinical proof-of-concept data. - Funding for companies in clinical phases, particularly Phase 3, has risen substantially. - Biotechs, having experienced lean years, are now opting for larger rounds to sustain operations until the next fundraise. - There is ample capital available, with approximately $39.7 billion in dry powder for life sciences venture deals. - Investors are prepared for longer-term investments, anticipating potential delays in IPOs and extended periods as private companies.   Given the recent surge in megaround financings and the increasing emphasis on clinical proof-of-concept data, it will be interesting to see how this trend will shape the landscape of biotech investments going forward, particularly in terms of valuations and the likelihood of successful IPO exits.

With the significant reduction of venture capital funding observed over the last two years, it is very important for early stage companies to collaborate with a CDMO aware and adapted to the resulting challenges. Novel operating models enabling timely and cost-effective ways-of-working to progress towards FIH clinical trials are key to permit early stage companies reaching their value inflection points. The ENABLE BIOTECH team has just created such a framework taking into consideration the challenges early stage companies face today.  

Global Digital Therapeutics (DTx) Startup Ecosystem: Deep Dive Analysis Through an extensive search and review of publicly available information, 172 startups were selected for detailed analysis based on specific criteria: Business Profile, Product, Technological Innovation including Patents, Investment and Fund Raising, Key Leadership, Revenue, Market, Clinical Trials, and Reimbursement Contents Global DTx Startup Landscape 1.5Q 2024 Global DTx Startups' Key Target Health Conditions 1.5Q 2024  Global DTx Product Landscape 1.5Q 2024  Global DTx Innovation (Patent) Landscape 1.5Q 2024 Partnerships between DTx Startups and Pharmaceuticals & Clinics 1.5Q 2024 Global DTx Startup Fund Raising Cases 1.5Q 2024 Conundrum in DTx Ecosystem Future of Global DTx Ecosystem Analysis Samples Expert invitation for comment: Koen Kas Tony J Simon, Ph.D. Kelly Stein-Marcus Marguerite Manteau-Rao, LCSW, MBA Janvi Parmar Ravi Janapureddy Howard Berman, PhD Seth Feuerstein Torsten Schröder, MD, PhD Logan Harper Stephen Hamm, MBA Bikram Gangwar Michaël Cardinal Sean G.(Sungjee) Kang, MD, MPH Robert A. Renata Redondo Bonaldi, PhD, Global MBA Ian Miller Jon Redmond Joshua Bull Klaudia Dobrev Marcelo Duhalde #digitaltherapeutics #dtx #startup #product #innovation #patent #fundraising #ecosystem 

#fundingalert 💼Company: NeuroTherapia, Inc. 💰Funding: $12.3 Million  ⚡Round: Series B  👥Investors: Cleveland Clinic, includes all previous investors, Brain Trust Accelerator Fund II, Dolby Family Ventures and the Alzheimer's Drug Discovery Foundation (ADDF) as well as new investors, Foundation for a Better World and CRUINT. NeuroTherapia is a clinical-stage, privately held biotechnology company Read more - To share your startup story write us on - contact@startuprise.io #startupfunding #boitechnology